RNLXY · Renalytix plc

On November 1, 2024, Icahn School of Medicine at Mount Sinai ("ISMMS") acquired 13,366,750 Ordinary Shares of the Issuer in a private placement of the Issuer (the "Private Placement") pursuant to the Subscription Letter dated as of September 30, 2024, after the Issuer's receipt of the requisite shareholder approval. In connection with the Private Placement, the Issuer, in two tranches, issued (a) an aggregate of 92,773,922 Ordinary Shares pursuant to a Placing Agreement with Oberon Investments Limited, (b) an aggregate of 38,387,634 Ordinary Shares (including the Ordinary Shares issued to ISMMS) to certain investors pursuant to Subscription Letters, and (c) an aggregate of 36,550,543 Ordinary Shares as a result of the restructuring of certain convertible bonds.

ISMMS acquired the Ordinary Shares for approximately $1.55 million, which is equivalent to a price of 9 pence per Ordinary Share (or approximately $0.116 per share based on a conversion rate of 1 GBP to $1.2920 on November 1, 2024).

The securities reported herein are held directly by ISMMS.

As the sole member of The Mount Sinai Hospital ("MSH"), Mount Sinai Hospitals Group, Inc. ("MSHG") may be deemed to beneficially own the securities held by MSH. As the sole member of MSHG, Mount Sinai Health System, Inc. ("MSHS") may be deemed to beneficially own the securities beneficially owned by MSHG. As the sole member of ISMMS, MSHS may be deemed to beneficially own the securities held by ISMMS. Each of the reporting persons disclaims beneficial ownership of all such securities reported herein, except to the extent of its pecuniary interest, if any.

The exercise price is 0.1625 pounds sterling. The U.S. dollar equivalent of the exercise price is $0.2067 using the Bank of England rate as of June 10, 2024 (1.00 pound sterling = $1.272).

One fourth (1/4th) of the shares subject to the option award shall vest on August 28, 2024, and the remaining shares shall vest in nine equal monthly installments thereafter, subject to the Reporting Person's continuous service.

On April 24, 2024, Icahn School of Medicine at Mount Sinai ("ISMMS") acquired 9,360,374 Ordinary Shares of the Issuer in the second tranche (the "Second Tranche") of a private placement of the Issuer (the "Private Placement") pursuant to the Placing Agreement dated March 12, 2024 with Stifel Nicolaus Europe Limited ("Stifel"). The Issuer issued 19,986,031 Ordinary Shares in the first tranche of the Private Placement, which was closed on March 14, 2024, and 26,815,841 Ordinary Shares in the Second Tranche, which was closed on April 24, 2024 after the receipt of the requisite shareholder approval.

ISMMS purchased the Ordinary Shares for approximately $2.3 million, which is equivalent to a price of 20 pence per Ordinary Share (or approximately $0.25 per share based on a conversion rate of 1 GBP to $1.2498 on April 23, 2024).

The securities reported herein are held directly by ISMMS.

As the sole member of The Mount Sinai Hospital ("MSH"), Mount Sinai Hospitals Group, Inc. ("MSHG") may be deemed to beneficially own the securities held by MSH. As the sole member of MSHG, Mount Sinai Health System, Inc. ("MSHS") may be deemed to beneficially own the securities beneficially owned by MSHG. As the sole member of ISMMS, MSHS may be deemed to beneficially own the securities held by ISMMS. Each of the reporting persons disclaims beneficial ownership of all such securities reported herein, except to the extent of its pecuniary interest, if any.

The exercise price is 0.245 pounds sterling. The U.S. dollar equivalent of the exercise price is $0.304 using the Bank of England rate as of November 17, 2023 (1.00 pound sterling = $1.243).

One twelfth (1/12th) of the shares subject to the option award shall vest in equal quarterly installments commencing on February 20, 2024, subject to the Reporting Person's continuous service.

The exercise price is 0.245 pounds sterling. The U.S. dollar equivalent of the exercise price is $0.304 using the Bank of England rate as of November 17, 2023 (1.00 pound sterling = $1.243).

One twelfth (1/12th) of the shares subject to the option award shall vest in equal quarterly installments commencing on February 20, 2024, subject to the Reporting Person's continuous service.

The exercise price is 0.245 pounds sterling. The U.S. dollar equivalent of the exercise price is $0.304 using the Bank of England rate as of November 17, 2023 (1.00 pound sterling = $1.243).

One twelfth (1/12th) of the shares subject to the option award shall vest in equal quarterly installments commencing on February 20, 2024, subject to the Reporting Person's continuous service.

The exercise price is 0.245 pounds sterling. The U.S. dollar equivalent of the exercise price is $0.304 using the Bank of England rate as of November 17, 2023 (1.00 pound sterling = $1.243).

One third (1/3rd) of the shares subject to the option award shall vest on September 1, 2024, and one eighth (1/8th) of the remaining shares subject to the option award shall vest in equal quarterly installments thereafter, subject to the Reporting Person's continuous service.

The exercise price is 0.245 pounds sterling. The U.S. dollar equivalent of the exercise price is $0.304 using the Bank of England rate as of November 17, 2023 (1.00 pound sterling = $1.243).

One twelfth (1/12th) of the shares subject to the option award shall vest in equal quarterly installments commencing on February 20, 2024, subject to the Reporting Person's continuous service.

The exercise price is 1.175 pounds sterling. The U.S. dollar equivalent of the exercise price is $1.506 using the Bank of England rate as of July 10, 2023 (1.00 pound sterling = $1.282).

One twelfth (1/12th) of the shares subject to the option award shall vest in equal quarterly installments commencing on October 10, 2023, subject to the Reporting Person's continuous service.

The exercise price is 1.025 pounds sterling. The U.S. dollar equivalent of the exercise price is $1.301 using the Bank of England rate as of July 6, 2023 (1.00 pound sterling = $1.269).

One twelfth (1/12th) of the shares subject to the option award shall vest in equal quarterly installments commencing on October 6, 2023, subject to the Reporting Person's continuous service.

The exercise price is 1.025 pounds sterling. The U.S. dollar equivalent of the exercise price is $1.301 using the Bank of England rate as of July 6, 2023 (1.00 pound sterling = $1.269).

One twelfth (1/12th) of the shares subject to the option award shall vest in equal quarterly installments commencing on October 6, 2023, subject to the Reporting Person's continuous service.

The exercise price is 1.025 pounds sterling. The U.S. dollar equivalent of the exercise price is $1.301 using the Bank of England rate as of July 6, 2023 (1.00 pound sterling = $1.269).

One twelfth (1/12th) of the shares subject to the option award shall vest in equal quarterly installments commencing on October 6, 2023, subject to the Reporting Person's continuous service.

The exercise price is 1.025 pounds sterling. The U.S. dollar equivalent of the exercise price is $1.301 using the Bank of England rate as of July 6, 2023 (1.00 pound sterling = $1.269).

One third (1/3rd) of the shares subject to the option award shall vest on July 6, 2024, and one eighth (1/8th) of the remaining shares subject to the option award shall vest in equal quarterly installments thereafter, subject to the Reporting Person's continuous service.

The exercise price is 1.025 pounds sterling. The U.S. dollar equivalent of the exercise price is $1.301 using the Bank of England rate as of July 6, 2023 (1.00 pound sterling = $1.269).

One twelfth (1/12th) of the shares subject to the option award shall vest in equal quarterly installments commencing on October 6, 2023, subject to the Reporting Person's continuous service.

The exercise price is 1.025 pounds sterling. The U.S. dollar equivalent of the exercise price is $1.301 using the Bank of England rate as of July 6, 2023 (1.00 pound sterling = $1.269).

One twelfth (1/12th) of the shares subject to the option award shall vest in equal quarterly installments commencing on October 6, 2023, subject to the Reporting Person's continuous service.